OTC CGM for non-diabetic wellness: what the data can tell you
An over-the-counter continuous glucose monitor estimates interstitial glucose trends without a prescription for people within its cleared population. It can show timing and patterns around meals, activity, sleep, and illness, but isolated spikes do not diagnose disease or prove that a food is harmful.
An OTC continuous glucose monitor can reveal interstitial-glucose trends and timing without a prescription for people within the device’s cleared population. For someone without diabetes, it may help run a structured observation around meals, activity, sleep, or illness. It does not diagnose diabetes, insulin resistance, “metabolic damage,” or food intolerance, and a single spike is not a disease finding. 1234
The product is most useful when the question is defined before the sensor is applied and when unexpected data are confirmed through an appropriate clinical pathway rather than interpreted by a wellness sales script.
OTC describes access, not unlimited use
FDA first cleared Stelo for adults 18 and older who do not use insulin, including people without diabetes who want to understand how diet and exercise may affect glucose. The original clearance excluded people with problematic hypoglycemia because the system was not designed to alert for that dangerous condition. 1 In June 2026, FDA cleared an expanded Stelo indication for people age two and older who do not use insulin. 2
Clearance belongs to the exact model, software and labeling. Other OTC CGMs can have different age, diabetes, medication, alert, wear, phone, and interpretation conditions. Read the current device instructions rather than treating “OTC CGM” as one universal product.
| Question | CGM can contribute | CGM cannot establish alone |
|---|---|---|
| Meal timing | Direction, peak timing and return pattern under that day's conditions | That one food is universally good, bad or intolerable |
| Activity | How a walk or workout coincides with a trend | Long-term disease prevention from one session |
| Sleep / stress | A pattern worth correlating over repeated days | A diagnosis of cortisol or sleep disorder |
| Possible abnormal glucose | A reason to save data and seek appropriate testing | Diabetes or prediabetes diagnosis |
| Low reading | A sensor signal to assess against symptoms and instructions | True blood hypoglycemia, especially when the device is not designed for that use |
| Program response | A behavioral feedback signal | Medication effectiveness or safety without clinical monitoring |
The sensor reads interstitial fluid, not a laboratory blood sample
The sensor estimates glucose in fluid between cells. Changes can lag blood glucose, especially during rapid rises or falls. Pressure on a sensor, insertion trauma, poor adhesion, hydration and perfusion context, temperature, interfering substances listed in labeling, software, and the first or last period of wear can affect a reading.
The FDA review for Stelo describes the intended measurement, app display, performance studies, warnings, and limitations. 3 Use the device’s instructions for when a reading does not match symptoms and whether confirmation with a blood-glucose meter or clinical test is indicated.
Do not compare a sensor number minute-for-minute with a fingerstick and assume the difference is device failure. They measure different compartments and have different error. Also do not use a smooth app line as if it were laboratory precision; every estimate has uncertainty.
An OTC sensor should not be used to make insulin decisions if its labeling excludes that use. “No prescription” does not mean “no risk from acting on the number.”
A spike needs a denominator and a question
Glucose normally changes after eating. The size and shape of a trace can depend on carbohydrate amount and form, fiber, protein, fat, prior meal, time of day, recent activity, sleep, stress, illness, menstrual context, medicines, alcohol, sensor lag, and starting value.
Apps may score a meal with proprietary thresholds. Ask how the score was validated, whether it applies to people without diabetes, and what meaningful outcome it predicts. A flat line is not always a health goal; it can be achieved by avoiding nutritious foods, under-eating, or manipulating meal order without evidence of long-term benefit.
Avoid turning one sensor into a restrictive diet. Fruit, legumes, whole grains, and other foods can create visible rises while contributing nutrients and dietary patterns not captured by a single glucose curve. Evaluate the whole meal, satiety, energy, gastrointestinal response, sustainability, and broader health context.
Build an experiment that can answer one thing
If the goal is learning, hold major variables steady. Compare the same meal on more than one day, at a similar time, with similar sleep and activity; change one factor such as a short post-meal walk. Record portion and timing without chasing decimal perfection.
A practical observation window might examine:
- repeated breakfast options under similar conditions;
- the same meal with and without activity;
- sleep duration and morning pattern over several days;
- illness or a medication change as context, without self-adjusting treatment; or
- how long the trace takes to return toward its starting range.
Define the endpoint before looking: peak timing, time above a device-defined range, variability, or simply whether a behavior is repeatable. Do not invent a diagnosis from a consumer score.
Diagnosis uses standardized clinical evidence
NIDDK describes A1C as one clinical test used to diagnose prediabetes and diabetes and explains conditions that can affect accuracy and the need for appropriate interpretation and confirmation. 4 Fasting plasma glucose and oral glucose tolerance testing are other standardized routes. A consumer CGM trace is not a replacement for those diagnostic criteria.
Repeated unexpectedly high readings, symptoms, pregnancy, medication effects, or known risk may justify appropriate evaluation. Save the time-stamped data, meals, symptoms, medicines, illness, and device lot rather than arriving with an app’s label alone.
Likewise, a low sensor reading without symptoms can be compression or sensor error, while a low reading with significant symptoms needs attention under the device instructions and appropriate care. Do not “treat the graph” with repeated sugar intake or supplements without confirming what is happening.
Wellness programs can add interpretation and privacy risk
A med spa or weight program may bundle a sensor with coaching, supplements, peptides, or GLP-1 care. Ask who interprets data, that person’s license and training, what clinical claims are made, how abnormal values are escalated, and whether recommendations are sponsored or limited to products the clinic sells.
CGM data can reveal meals, sleep periods, activity, illness, medication timing, pregnancy-related context, and daily routine. Read the device and coaching-app privacy notices. Identify who receives raw readings, derived scores, meal photos, location or wearable data; whether data train models or support advertising; retention and deletion; and whether revoking access removes downstream copies.
Avoid sharing login credentials with a clinic. Use the intended clinician-sharing function and remove access when the program ends. Export a personal copy before deleting an account if the data will inform medical care.
The adhesive and insertion site are part of the device
A sensor also creates a skin exposure. Follow the labeled site, preparation, wear time, water and adhesion instructions. Rotating sites and avoiding already irritated, scarred, infected, or unsuitable skin can matter. Do not improvise barrier products, overpatches, or adhesives without checking whether they interfere with insertion, signal, ventilation, or the manufacturer’s instructions.
Photograph and save the lot if a marked rash, drainage, increasing pain, bleeding, or device breakage occurs. A wellness coach should not diagnose an adhesive reaction through a glucose chat. Stop or seek appropriate help according to the device instructions and symptom severity, and report device problems through the manufacturer or FDA pathway when applicable.
A disciplined OTC-CGM workflow
- 1. Check the exact indication Match age, insulin use, hypoglycemia history, medicines, phone, alerts and intended use to the current device labeling.
- 2. Define one observation Choose a meal, activity, sleep or timing question and a simple endpoint before seeing the graph.
- 3. Control major variables Repeat comparable conditions, log portion and timing, and change one factor rather than drawing a conclusion from one day.
- 4. Respect measurement limits Account for interstitial lag, compression, adhesion, interfering substances, symptoms and label instructions for confirmation.
- 5. Escalate data appropriately Use standardized tests and qualified interpretation for diagnosis; save traces and context when readings are repeatedly unexpected.
- 6. Audit the data program Identify every app, coach, clinic, recipient, model-training use, retention period, deletion path and commercial recommendation.
An OTC CGM can be a useful mirror for a well-designed question. It becomes misleading when a wellness score is treated as a diagnosis or a normal fluctuation is sold as a problem requiring a product.
Sources
- U.S. Food and Drug Administration. FDA clears first over-the-counter continuous glucose monitor. FDA clearance announcement used for the original adult OTC Stelo indication, non-insulin-user boundary, limitations around problematic hypoglycemia, and direct-to-consumer access. Accessed .
- U.S. Food and Drug Administration. FDA clears first over-the-counter continuous glucose monitor for children. June 2026 FDA announcement used for the expanded age-two-and-older non-insulin-user indication and current device-population context. Accessed .
- U.S. Food and Drug Administration. Stelo Glucose Biosensor System 510(k) decision summary (K234070). Official review used for intended use, interstitial-fluid measurement, display cadence, performance, interfering substances, limitations, warnings, and app-based data flow. Accessed .
- National Institute of Diabetes and Digestive and Kidney Diseases. The A1C test and diabetes. NIH institute guidance used to distinguish a cleared consumer trend device from standardized diagnostic testing and to explain that diagnosis requires health-care interpretation and confirmation. Accessed .